Skip to main content
Terug
Watch Compare

Journey Medical Corp

Datakwaliteit: 100%
DERM
Nasdaq Manufacturing Chemicals
€ 5,24
▼ € 0,09 (-1,69%)
Marktkapitalisatie: 174,26 M
Prijs
€ 5,24
Marktkapitalisatie
174,26 M
Dagbereik
€ 5,00 — € 5,38
52-Weeksbereik
€ 4,31 — € 9,56
Volume
101.804
Openen € 5,33
50D / 200D Gem.
€ 7,55
30,56% below
50D / 200D Gem.
€ 7,54
30,53% below

Quick Summary

Belangrijkste Punten

Revenue declined -0,51% annually over 5 years
Negative free cash flow of -12,44 M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 10,71%

Groei

Revenue Growth (5Y)
-0,51%
Onder sectorgemiddelde (9,35%)
Revenue (1Y)10,20%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-50,64%
Boven sectorgemiddelde (-51,02%)
ROIC-14,99%
Net Margin-18,48%
Op. Margin-13,21%

Veiligheid

Debt / Equity
0,97
Boven sectorgemiddelde (0,33)
Current Ratio1,42
Interest Coverage-2,21

Waardering

PE (TTM)
-15,24
Onder sectorgemiddelde (-1,98)
P/B Ratio6,73
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (44 peers)
Metriek Aandeel Sector Mediaan
P/E -15,2 -2,0
P/B 6,7 5,1
ROE % -50,6 -51,0
Net Margin % -18,5 -150,2
Rev Growth 5Y % -0,5 9,3
D/E 1,0 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) 10,20% Revenue Growth (3Y) -11,61%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -0,51% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 61,86 M Net Income (TTM) -11,43 M
ROE -50,64% ROA -13,74%
Gross Margin N/A Operating Margin -13,21%
Net Margin -18,48% Free Cash Flow (TTM) -12,44 M
ROIC -14,99% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,97 Current Ratio 1,42
Interest Coverage -2,21 Asset Turnover 0,74
Working Capital 16,67 M Tangible Book Value -2,77 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -15,24 Forward P/E N/A
P/B Ratio 6,73 P/S Ratio 2,82
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -7,14%
Market Cap 174,26 M Enterprise Value 174,48 M
Per Share
EPS (Diluted TTM) -0,47 Revenue / Share 1,86
FCF / Share -0,37 OCF / Share -0,37
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 108,84%
SBC-Adj. FCF -18,59 M Growth Momentum 10,71

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 61,86 M 56,13 M 79,18 M 73,67 M 63,13 M
Net Income -11,43 M -14,67 M -3,85 M -29,63 M -43,99 M
EPS (Diluted) -0,47 -0,72 -0,21 -1,69 -4,32
Gross Profit — — — — —
Operating Income -8,17 M -13,68 M -2,07 M -27,52 M -34,88 M
EBITDA — — — — —
R&D Expenses 480.000,0 9,86 M 7,54 M 10,94 M 2,74 M
SG&A Expenses 44,37 M 40,20 M 43,91 M 59,47 M 39,83 M
D&A — — — — 0,0
Interest Expense 3,70 M 2,70 M 1,70 M 2,02 M 7,03 M
Income Tax 60.000,0 61.000,0 221.000,0 63.000,0 1,63 M

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 94,59 M 80,24 M 76,85 M 105,16 M 97,28 M
Total Liabilities 62,74 M 60,17 M 56,50 M 88,18 M 55,24 M
Shareholders' Equity 31,85 M 20,07 M 20,35 M 16,98 M 42,04 M
Total Debt 25,28 M 24,88 M 14,62 M 27,77 M —
Cash & Equivalents 24,09 M 20,31 M 27,44 M 32,00 M 49,08 M
Current Assets 66,87 M 48,18 M 56,46 M 77,68 M 84,49 M
Current Liabilities 37,44 M 35,18 M 41,87 M 66,83 M 51,61 M